ArticleWorld journal of gastroenterology2015
Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 140 citations in OpenAlex.
- Correlation of the expression of mismatch repair proteins, CDX2, and SATB2 with the clinicopathological parameters of patients with colorectal carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Dynamics and master transcription factors dependence of intestinal super-enhancers during differentiation and oncogenesis.Nucleic acids research · 2026Article
- Role of CDX2 in the prognosis of colorectal cancer across stages 0-IV.Oncology letters · 2026Article
- Colorectal Micropapillary Adenocarcinoma: Molecular Mechanisms and Clinical Implications.Journal of gastrointestinal cancer · 2026Review
- CANDiT: A machine learning framework for differentiation therapy in colorectal cancer.Cell reports. Medicine · 2025Article
- Colorectal clear cell carcinoma: a literature review.Journal of medical case reports · 2025Review
- CDX2 loss in colorectal cancer cells is associated with invasive properties and tumor budding.Scientific reports · 2025Article
- Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies.NPJ precision oncology · 2025Review
- Clinicopathological and molecular features of genome-stable colorectal cancers.Histology and histopathology · 2025Article
- CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer.Cancer immunology, immunotherapy : CII · 2025Article
- A brief review of Lynch syndrome: understanding the dual cancer risk between endometrial and colorectal cancer.Oncology reviews · 2025Review
- The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers.Journal of pathology and translational medicine · 2025Article
- Molecular Biology of Cancer-Interplay of Malignant Cells with Emerging Therapies.International journal of molecular sciences · 2024Article
- The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer.International journal of molecular sciences · 2024Article
- Evaluation of the Immunohistochemical Scoring System of CDX2 Expression as a Prognostic Biomarker in Colon Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.Medical molecular morphology · 2024Article
- Tissue-location-specific transcription programs drive tumor dependencies in colon cancer.Nature communications · 2024Article
- Loss ofEcancermedicalscience · 2024Article
- Hippo Signaling Pathway in Colorectal Cancer: Modulation by Various Signals and Therapeutic Potential.Analytical cellular pathology (Amsterdam) · 2024Review
- Caudal-Type Homeobox Transcription Factor 2 is a Favorable Prognostic Indicator in Stage II and III Gastric Cancer Following Curative Surgery.International journal of general medicine · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the clinicopathologic characteristics and prognostic implications associated with loss of CDX2 expression in colorectal cancers (CRCs).
methodsWe immunohistochemically evaluated CDX2 expression in 713 CRCs and paired our findings to clinicopathologic and molecular characteristics of each individual. Endpoints included cytokeratin 7 and CK20 expression, microsatellite instability, CpG island methylator phenotype, and KRAS and BRAF mutation statuses. Univariate and multivariate survival analysis was performed to reveal the prognostic value of CDX2 downregulation.
resultsCDX2 expression was lost in 42 (5.9%) patients. Moreover, loss of CDX2 expression was associated with proximal location, infiltrative growth, advanced T, N, M and overall stage. On microscopic examination, loss of CDX2 expression was associated with poor differentiation, increased number of tumor-infiltrating lymphocytes, luminal serration and mucin production. Loss of CDX2 expression was also associated with increased CK7 expression, decreased CK20 expression, CpG island methylator phenotype, microsatellite instability and BRAF mutation. In a univariate survival analysis, patients with loss of CDX2 expression showed worse overall survival (P < 0.001) and progression-free survival (P < 0.001). In a multivariate survival analysis, loss of CDX2 expression was an independent poor prognostic factor of overall survival [hazard ratio (HR) = 1.72, 95%CI: 1.04-2.85, P = 0.034] and progression-free survival (HR = 1.94, 95%CI: 1.22-3.07, P = 0.005).
conclusionLoss of CDX2 expression is associated with aggressive clinical behavior and can be used as a prognostic marker in CRCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.